相关实验视频

Updated: Jul 9, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

描述和验证CD81作为肺状细胞癌的潜在标

Xifu Ye¹, Junyuan Deng¹, Chengyuan Dong²

¹Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Biochemical and biophysical research communications

|December 9, 2023

概括

CD81蛋白是肺状细胞癌 (LUSC) 的危险因素,促进瘤生长并阻碍免疫治疗. 向CD81可能会改善LUSC患者的化疗反应.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
分子生物学分子生物学

背景情况:

CD81是一种四氨酸蛋白,调节细胞信号和免疫反应.
CD81影响癌症的发展和对免疫治疗的反应.

研究的目的:

研究CD81在肺状细胞癌 (LUSC) 和肺腺癌中的作用.
在LUSC中确定CD81对瘤特征和治疗反应的影响.

主要方法:

对基因表达数据的生物信息分析.
功能性实验涉及LUSC细胞中CD81枯竭.

主要成果:

CD81在LUSC中起到风险因素的作用,但在肺腺癌中起到保护作用.
在LUSC中高CD81表达与激活的自和JAK-STAT信号相关.
CD81与瘤突变负担,微卫星不稳定性和LUSC中的新抗原负相关.
高CD81的LUSC患者对免疫疗法没有反应,但可以从化疗中受益.
CD81的枯竭抑制了LUSC细胞的增殖,并增加了对西斯的敏感性.

结论:

在LUSC中,CD81是基斯普拉丁基化疗的潜在治疗标.
调节CD81可能为LUSC提供新的治疗策略.

关键词:

在CD81 CD81 西斯普拉丁 (Cisplatin) 是一种肺状细胞癌是肺的状细胞癌.

更多相关视频

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

Published on: May 11, 2016

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频